CVN424 (CVN424) — Research Compounds Library | RetatrutideCompare
GPR6 inverse agonist developed by Cerevance for Parkinson's disease motor fluctuations. Phase 2 trial reported reduced OFF time without dyskinesia signals.
GPR6 inverse agonist developed by Cerevance for Parkinson's disease motor fluctuations. Phase 2 trial reported reduced OFF time without dyskinesia signals.